Stock Market Reviews

ELVN (Enliven Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ELVN (Enliven Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k
  The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.
  Feb 1, 2026 - $ELVN
• Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data
  Enliven Therapeutics (ELVN) shares are in focus after the company reported encouraging initial Phase 1b data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients, with efficacy and safety outcomes comparing favorably to existing BCR::ABL1 TKIs. See our latest analysis for Enliven Therapeutics. The latest clinical update appears to have quickly fed into sentiment, with a 1-day share price return of 50.29% at a last close of US$23.25 and year to date share price return of...
  Jan 9, 2026 - $ELVN
• Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).
  Jan 8, 2026 - $ELVN
• Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effective January 7, 2026, as the Company transitions its focus to late-stage development and commercialization.
  Jan 7, 2026 - $ELVN
• Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
  Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment.
  Dec 11, 2025 - $ELVN
• Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Rick Fair as Chief Executive Officer and member of the Board of Directors of Enliven, effective December 11, 2025. Sam Kintz, Co-Founder and former Chief Executive Officer of Enliven, will assume a new role as Head of Pipeline, also effective December 11, 2025. The transition plan
  Dec 11, 2025 - $ELVN
• Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress
  Enliven Therapeutics (ELVN) has been quietly grinding through its clinical pipeline, and the stock’s recent move offers a useful snapshot of how investors are weighing early trial risk against long term oncology potential. See our latest analysis for Enliven Therapeutics. The latest pullback to a $20.52 share price comes after a solid 1 month share price return of 16.39%. However, the 1 year total shareholder return of negative 15.97% shows longer term sentiment is still cautious, suggesting...
  Dec 9, 2025 - $ELVN
• Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
  The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Dec 3, 2025 - $ELVN
• Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect?
  The mean of analysts' price targets for Enliven Therapeutics, Inc. (ELVN) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 17, 2025 - $ELVN
• /C O R R E C T I O N -- Enliven Therapeutics, Inc./
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update, including highlights of pipeline progress.
  Nov 13, 2025 - $ELVN